These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2248087)

  • 1. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days.
    Guentert TW; Tucker G; Korn A; Pfefen JP; Haefelfinger P; Schoerlin MP
    Acta Psychiatr Scand Suppl; 1990; 360():91-3. PubMed ID: 2248087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.
    Schoerlin MP; Mayersohn M; Korn A; Eggers H
    Clin Pharmacol Ther; 1987 Oct; 42(4):395-404. PubMed ID: 3665338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function.
    Stoeckel K; Pfefen JP; Mayersohn M; Schoerlin MP; Andressen C; Ohnhaus EE; Frey F; Guentert TW
    Acta Psychiatr Scand Suppl; 1990; 360():94-7. PubMed ID: 2248088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species-specific biotransformation of moclobemide: a comparative study in rats and humans.
    Schoerlin MP; Da Prada M
    Acta Psychiatr Scand Suppl; 1990; 360():108-10. PubMed ID: 2248061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.
    Mayersohn M; Guentert TW
    Clin Pharmacokinet; 1995 Nov; 29(5):292-332. PubMed ID: 8582117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.
    Schoerlin MP; Mayersohn M; Hoevels B; Eggers H; Dellenbach M; Pfefen JP
    Clin Pharmacol Ther; 1991 Jan; 49(1):32-8. PubMed ID: 1988238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
    Holford NH; Guentert TW; Dingemanse J; Banken L
    Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moclobemide excretion in human breast milk.
    Pons G; Schoerlin MP; Tam YK; Moran C; Pfefen JP; Francoual C; Pedarriosse AM; Chavinie J; Olive G
    Br J Clin Pharmacol; 1990 Jan; 29(1):27-31. PubMed ID: 2297459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
    Wiesel FA; Raaflaub J; Kettler R
    Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food intake on the relative bioavailability of moclobemide (Ro 11-1163).
    Schoerlin MP; Mayersohn M; Hoevels B; Eggers H; Dellenbach M; Pfefen JP
    J Neural Transm Suppl; 1988; 26():115-21. PubMed ID: 3283288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function.
    Schoerlin MP; Horber FF; Frey FJ; Mayersohn M
    J Clin Pharmacol; 1990 Mar; 30(3):272-84. PubMed ID: 2312783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine.
    Schoerlin MP; Blouin RA; Pfefen JP; Guentert TW
    Acta Psychiatr Scand Suppl; 1990; 360():98-100. PubMed ID: 2248089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotransformation of moclobemide in humans.
    Jauch R; Griesser E; Oesterhelt G; Arnold W; Meister W; Ziegler WH; Guentert TW
    Acta Psychiatr Scand Suppl; 1990; 360():87-90. PubMed ID: 2248086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects.
    Dingemanse J; Wood N; Guentert T; Oie S; Ouwerkerk M; Amrein R
    Psychopharmacology (Berl); 1998 Nov; 140(2):164-72. PubMed ID: 9860107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man.
    Raaflaub J; Haefelfinger P; Trautmann KH
    Arzneimittelforschung; 1984; 34(1):80-2. PubMed ID: 6538424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients.
    Ignjatovic AR; Miljkovic B; Todorovic D; Timotijevic I; Pokrajac M
    J Clin Pharmacol; 2011 May; 51(5):661-71. PubMed ID: 20495135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
    Zimmer R; Fischbach R; Breuel HP
    Acta Psychiatr Scand Suppl; 1990; 360():76-7. PubMed ID: 2248082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.
    Gram LF; Guentert TW; Grange S; Vistisen K; Brøsen K
    Clin Pharmacol Ther; 1995 Jun; 57(6):670-7. PubMed ID: 7781267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
    Dingemanse J; Korn A; Pfefen JP; Güntert TW
    Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.